Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The initial recombinant protein vaccines have produced antibodies during preclinical testing in mice, said Zhejiang Science and Technology department official at a press conference.

The department’s deputy director Song Zhiheng added that mRNA vaccines have also advanced into the animal experiment stage.

Animal testing for recombinant adenovirus vector vaccines could be initiated soon, while virus strains selection has progressed into the fourth generation.

Commenting on the progress, Song said: “At present, researchers are racing against the clock and working hard to overcome difficulties.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“But it is also important to realise that due to the relatively long period of vaccine development, scientific laws must be respected and a scientific, rigorous and safe research process must be followed.

Earlier this month, Imperial College London researchers in the UK started animal testing a novel coronavirus vaccine. This announcement was followed by the progress of Serum Institute of India and Codagenix’s vaccine candidate into preclinical phase.


See all Coronavirus vaccines and drugs in the pipeline


At a meeting held on 11 and 12 February in Geneva, World Health Organization (WHO) director-general Dr Tedros Adhanom Ghebreyesus said that a vaccine for the novel coronavirus may be available in 18 months.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact